Announcements
- Inventiva fait le point sur son programme clinique NATiV3 évaluant lanifibranor dans la MASH/NASH et sur sa situation financièr
- Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
- DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024
- Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
- Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
- Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024
- Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024
- Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024
- Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
- Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires
More ▼
Key statistics
On Tuesday, Inventiva SA (0RNK:LSE) closed at 2.81, 0.36% above its 52-week low of 2.80, set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 2.81 |
Average volume | 17.00 |
---|---|
Shares outstanding | 52.48m |
Free float | 42.01m |
P/E (TTM) | -- |
Market cap | 145.36m EUR |
EPS (TTM) | -2.45 EUR |
Data delayed at least 20 minutes, as of Jul 02 2024 10:51 BST.
More ▼